By Fineline Cube 
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced a five-year investment plan totaling USD 50 billion in the United States. The initiative aims to significantly strengthen its operational footprint in the country through strategic expansions and new facilities.
Investment Highlights
The investment will focus on expanding and upgrading U.S. manufacturing and distribution capabilities for innovative medicines and diagnostics across facilities in Kentucky, Indiana, New Jersey, Oregon, and California. Plans include constructing a state-of-the-art gene therapy manufacturing facility in Pennsylvania and establishing a 900,000-square-foot manufacturing center dedicated to next-generation weight loss therapies. Additionally, Roche will build a new continuous glucose monitoring (CGM) production facility in Indiana and launch an AI-driven R&D hub in Massachusetts to advance research in cardiovascular, renal, and metabolic diseases. The company will also significantly expand its pharmaceuticals and diagnostics R&D centers in Arizona, Indiana, and California.
Growth and Impact
Currently operating 24 facilities and employing over 25,000 staff across eight U.S. states, Roche plans to expand its U.S. infrastructure to 13 manufacturing sites and 15 R&D centers across its Pharmaceuticals and Diagnostics divisions. The initiative is projected to create over 12,000 new jobs, including approximately 6,500 temporary construction roles and 1,000 permanent positions at new or expanded facilities. Upon full operationalization of the new capacity, Roche expects the U.S. to transition into a net exporter of medicines, reversing its current import dependency. Notably, its Diagnostics Division already maintains a trade surplus in U.S.-manufactured products for global markets.-Fineline Info & Tech